- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06651229
Um estudo de JNJ-90189892 para leucemia mieloide aguda recidivante ou refratária ou neoplasias mielodisplásicas
Um estudo de fase 1, primeiro em humanos, de escalonamento de dose de JNJ-90189892 para leucemia mieloide aguda recidivante ou refratária ou neoplasias mielodisplásicas
The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Concord, Austrália, 2139
- Concord Hospital
-
Melbourne, Austrália, 3000
- Peter MacCallum Cancer Centre
-
Nedlands, Austrália, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Madrid, Espanha, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, Espanha, 31008
- Clinica Univ. de Navarra
-
Seville, Espanha, 41013
- Hospital Universitario Virgen Rocio
-
-
-
-
-
Marseille, França, 13273
- Institut Paoli-Calmettes
-
Strasbourg, França, 67200
- CHRU de Strasbourg - Hopital de Hautepierre
-
Toulouse, França, 31100
- Institut Claudius Regaud
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
- Body weight that is greater than or equals to (>=) 40 kg
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
- Participants must have laboratory parameters in the required range
Exclusion Criteria:
- Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
- Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
- All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
- Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
- Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Has known active central nervous system involvement
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: JNJ-90189892: Monotherapy
Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1. |
JNJ-90189892 will be administered. |
|
Experimental: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)
Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET. |
JNJ-90189892 will be administered. AZA will be administered. VEN will be administered. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Adverse events (AEs) by Severity
Prazo: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Prazo: At least 14 days
|
DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity. |
At least 14 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Serum Concentration of JNJ-90189892
Prazo: Up to approximately 2.5 years
|
Serum samples will be analyzed to determine concentrations of JNJ-90189892. |
Up to approximately 2.5 years
|
|
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Prazo: Up to approximately 2.5 years
|
AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Prazo: Up to approximately 2.5 years
|
Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Prazo: Up to approximately 2.5 years
|
Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Prazo: Up to approximately 2.5 years
|
Participants with presence of anti-JNJ-90189892 antibodies will be reported. |
Up to approximately 2.5 years
|
|
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Prazo: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria. |
Up to approximately 2.5 years
|
|
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Prazo: Up to approximately 2.5 years
|
OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria. |
Up to approximately 2.5 years
|
|
Complete Response in MDS
Prazo: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria. |
Up to approximately 2.5 years
|
|
Duration of Response (DOR)
Prazo: Up to approximately 2.5 years
|
DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first. |
Up to approximately 2.5 years
|
|
Time to Response (TTR)
Prazo: Up to approximately 2.5 years
|
TTR is defined for responders, as the time from the first dose of study drug to first qualifying response. |
Up to approximately 2.5 years
|
|
Number of Participants Achieving Transfusion Independence
Prazo: Up to approximately 2.5 years
|
Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS. |
Up to approximately 2.5 years
|
|
Part 4 Only: Overall Survival (OS)
Prazo: Up to approximately 2.5 years
|
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. |
Up to approximately 2.5 years
|
|
Part 4 Only: Event-Free Survival (EFS)
Prazo: Up to approximately 2.5 years
|
EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first. |
Up to approximately 2.5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 90189892AML1001
- 2024-514341-10-00 (Identificador de registro: EUCT number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .